Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

globenewswire.com - Pharma Equity Group A/S - Pharma Equity Group consolidated Interim Report 1 January - 30 June 2026
Pharma Equity Group consolidated Interim Report 1 January - 30 June 2026
GlobeNewswire

Consolidated Interim Report 1 January – 30 June 2026 On 14 August 2026, the Board of Directors and the Executive Board of Pharma Equity Group A/S ('PEG', 'The Company' or the 'Group') considered and approved the interim report for the Group…

bloomberg.com - Bastian Benrath-Wright - Swiss Economy Surges Far More Than Forecast, Led by Pharma
Swiss Economy Surges Far More Than Forecast, Led by Pharma
Bloomberg

Swiss growth momentum surged to the fastest pace since 2021, highlighting the economy's resilience to higher energy costs and lingering trade uncertainty. Gross domestic product adjusted for large sport events rose 1.5% in the second quarter from…

seekingalpha.com - SA Transcripts - Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript
Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript
Seeking Alpha

Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call August 14, 2026 9:00 AM EDT Panna Sharma - President, CEO & Director David Margrave - CFO & Secretary Good morning and welcome to our Second Quarter 2026 Earnings call. As a reminder, this call is…

thehindu.com - N. Ravi Kumar - U.S. FDA issues warning letter to Aurobindo Pharma's subsidiary Eugia Pharma
U.S. FDA issues warning letter to Aurobindo Pharma's subsidiary Eugia Pharma
The Hindu

A formulation manufacturing facility of Aurobindo Pharma subsidiary near Hyderabad has been issued a warning letter by the U.S. Food and Drug Administration (U.S. FDA). The action on the facility of Eugia Pharma Specialities, the subsidiary…

fool.com - Erin Kennedy - Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?
Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?
The Motley Fool

While Fidelity MSCI Health Care Index ETF (FHLC -0.20%) provides broad healthcare exposure at a very low cost, iShares U.S. Pharmaceuticals ETF (IHE +0.01%) offers a concentrated focus on the domestic pharmaceutical sector for investors seeking…

thehindubusinessline.com - Aurobindo Pharma arm Eugia Pharma's Telangana unit gets warning letter from USFDA
Aurobindo Pharma arm Eugia Pharma's Telangana unit gets warning letter from USFDA
BusinessLine

Aurobindo Pharma on Friday said the US health regulator has issued a warning letter to a formulation manufacturing facility of its arm, Eugia Pharma Specialities Ltd, in Telangana. In May this year the company had stated that the US Food and Drug…

thehindubusinessline.com - Natco Pharma's Q1 net down 57% at ₹206 crore; to raise ₹2,000 crore
Natco Pharma's Q1 net down 57% at ₹206 crore; to raise ₹2,000 crore
BusinessLine

Natco Pharma's consolidated net profit declined 57 per cent at ₹206 crore in the first quarter ended June 30, 2026, compared to ₹480 crore for the corresponding quarter last year. The total revenue of the Hyderabad based company stood…

marketbeat.com - Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up - What's Next?
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up - What's Next?
MarketBeat

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report)'s stock price gapped up before the market opened on Friday. The stock had previously closed at $19.23, but opened at $20.30. Nuvectis Pharma shares last traded at $19.1150, with a volume of…

globenewswire.com - Pharma Equity Group A/S - Correction to Consolidated Interim Report 1 January - 30 June 2026
Correction to Consolidated Interim Report 1 January - 30 June 2026
GlobeNewswire

Correction to Consolidated Interim Report 1 January – 30 June 2026 The previous announcement with the half year report was missing the report. The announcement is re-published, including the report. On 14 August 2026, the Board of Directors…

thehindubusinessline.com - KS Badri Narayanan - Q1 Results 14th Aug Highlights: BDL, Ashok Leyland, 3M India Q1 PAT rise y-o-y, Electrotherm, NATCO Pharma, Alkem Lab PAT decline, NMDC, Voltas, Cochin Shipyard, Physicswallah, PTC Ind, Borosil to announce Q1 results
Q1 Results 14th Aug Highlights: BDL, Ashok Leyland, 3M India Q1 PAT rise y-o-y, Electrotherm, NATCO Pharma, Alkem Lab PAT decline, NMDC, Voltas, Cochin Shipyard, Physicswallah, PTC Ind, Borosil to announce Q1 results
BusinessLine

Q1 Results Today, 14th August 2026 Highlights: Find all the latest Q1 results 2026 updates of Ashok Leyland, NMDC, Alkem Laboratories, Bharat Dynamics, Voltas, 3M India, Cochin Shipyard, Physicswallah, Cholamandalam Financial Holdings, PTC…

mumsnet.com - US government report reveals mass insurance fraud in the gender change industry
US government report reveals mass insurance fraud in the gender change industry
Mumsnet

Please or to access all these features Feminism: Sex and gender discussions Big news. The extent of this is appalling, but not surprising. With WPATH admitting its ideas have no basis the foundations behind the huge gender medical industry in the…

forbes.com - Bill Oldham - Applying A Marketplace Model To Healthcare Benefits
Applying A Marketplace Model To Healthcare Benefits
Forbes

Bill Oldham is President of AscellaHealth, a global healthcare company enabling access to therapies for rare and complex conditions. Imagine a random Tuesday afternoon in late August. While much of corporate America is still in summer vacation…

cyclingnews.com - Matilda Price - Czech Tour: Netcompany Ineos dominate stage 2 to deliver AJ August to mountaintop victory and race lead
Czech Tour: Netcompany Ineos dominate stage 2 to deliver AJ August to mountaintop victory and race lead
Cyclingnews

AJ August capitalised on a strong Netcompany Ineos team effort to soar to victory and into the race lead on stage 2 of the Czech Tour, finishing atop a 15km climb to Ještěd. Ineos had paced for almost all of the long final climb, with…

fool.com - Eric Volkman - BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.
BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.
The Motley Fool

One of the more high-flying stocks in the U.S. biotech sector these days is genetic-disease-focused BridgeBio Pharma (BBIO -1.81%). That's due almost entirely to the outperformance of its Attruby heart medication. If the generally bullish analyst…

fool.com - Thomas Niel - Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
The Motley Fool

In recent weeks, two pharmaceutical stocks, AstraZeneca (AZN -0.80%) and Bristol Myers Squibb (BMY +1.49%), have become the subject of merger rumors. At the start of the month, the Financial Times dropped a potential bombshell when, in an exclusive…

Receive a Daily briefing on Pharma Industry News

Get Started